MedTrace Logo

Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury

NCT00445809 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 355

Last updated 2009-08-04

No results posted yet for this study

Summary

Some patients who undergo cardiovascular surgery requiring cardiopulmonary bypass will develop a kidney injury following their surgery. The purpose of this study is to take a blood sample from patients before they have this type of surgery and then at nine time points after their surgery to test their plasma for a biomarker called NGAL and compare the NGAL levels to their creatinine levels. We hypothesize that NGAL is an earlier marker for kidney injury than creatinine.

Conditions

  • Kidney Failure, Acute

Sponsors & Collaborators

  • Abbott RDx Cardiometabolic

    lead OTHER

Principal Investigators

  • Emil Paganini, MD · The Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-12-31
Completion
2009-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00445809 on ClinicalTrials.gov